Michail Ignatiadis - Concepedia

Author

Michail Ignatiadis

Also Known As

Ignatiadis, Michail, M Ignatiadis, M. Ignatiadis, M.G. Ignatiadis, Michael Misialek, Michail G Ignatiadis, Michail Ignatiadis

319

Publications

15.3K

Citations

H-Index

Concepts

All Affiliations

Institut Jules Bordet Université Libre de Bruxelles Dana-Farber Cancer Institute European Institute of Oncology KU Leuven

About

Michail Ignatiadis is an author at Institut Jules Bordet specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	24	4K
2	Health Sciences	6	6	1.1K
3	Engineering	3	3	91
4	Public Health	3	3	164
5	Biomedical Engineering	1	1	12

Michail Ignatiadis

Publications

8.5K

Citations

H-Index

Page 1

	Year	Citations
CD4+ follicular helper T cell infiltration predicts breast cancer survival Chunyan Gu‐Trantien, Sherene Loi, Soizic Garaud, Journal of Clinical Investigation Lymphocyte DevelopmentT-regulatory CellImmunologyImmune RegulationImmunoediting	2013	1K
Subclonal diversification of primary breast cancer revealed by multiregion sequencing Lucy Yates, Moritz Gerstung, Stian Knappskog, Nature Medicine Breast OncologyOncologyTumor HeterogeneityMedicinePathology	2015	815
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data François‐Clément Bidard, Dieter Peeters, Tanja Fehm, The Lancet Oncology Metastatic Breast CancerBreast OncologyClinical ValidityIndividual Patient DataMedicine	2014	815
Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling Hatem A. Azim, Stefan Michiels, Philippe L. Bédard, Clinical Cancer Research	2012	418
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer Kamal S. Saini, Sherene Loi, Evandro de Azambuja, Cancer Treatment Reviews Breast OncologyOncologyMedicineRaf/mek/erk PathwaysBreast Cancer	2013	370
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis Yacine Barèche, David Venet, Michail Ignatiadis, Annals of Oncology	2018	346
Different Prognostic Value of Cytokeratin-19 mRNA–Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer Michail Ignatiadis, N. Xenidis, Maria Perraki, Journal of Clinical Oncology	2007	240
Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer Nikolaos Xenidis, Michail Ignatiadis, Stella Apostolaki, Journal of Clinical Oncology	2009	240
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer Françoise Rothé, J.-F. Laes, Diether Lambrechts, Annals of Oncology Breast OncologyOncologyCancer PathologyMutational AnalysisTumor Heterogeneity	2014	234
Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer Michail Ignatiadis, Galatea Kallergi, Maria Ntoulia, Clinical Cancer Research	2008	231

Page 1